After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the
German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP)